12/17/25, 3:46 PM APHON Overview Exam || 2025 (Actual Exam) Questions with verified Answers (Latest Update 2025) UPDATE!! Flashcards | Quiz…
APHON Overview Exam || 2025 (Actual Exam)
Questions with verified Answers (Latest Update
2025) UPDATE!!
Save
Terms in this set (299)
modality of tx: agents that resemble body's own
defense and surveillance systems. can
biotherapy augment/modulate/restore host's immune response,
direct antitumor activity, other biological effects. side
effects typically hypersensitivity rx
tumor cells express abnormal tumor antigens on
immune surveillance surface that can be recognized/destroyed by immune
system
natural killer cells lymphocyte that recognizes/kills malignant cells
cytotoxic t cells recognize tumor-assosiated antigens and kills cells
multiple moa's & produced w/ recombinant dna.
protein capable of protecting other cells from viral
interferons infections by interfering w/ viral replication.
family of glycoproteins include: antiviral,
antiproliferative, potent immunomodulatory effects
products of immune cells to enhance cytotoxic
cytokines
activity of cells and increase immune response
leukocyte-derived. tx: hairy cell leukemia, melanoma,
alpha-interferon chronic myeloid leukemia, follicular lymphoma,
multiple myeloma, cutaneous t-cell lymphoma
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 1/29
,12/17/25, 3:46 PM APHON Overview Exam || 2025 (Actual Exam) Questions with verified Answers (Latest Update 2025) UPDATE!! Flashcards | Quiz…
beta-interferon fibroblast-derived. tx MS
t-lymphocyte derived. tx chronic granulomatus
gamma-interferon
disease
produced by t-helper cells & stimulate
growth/maturation of t-cell subsets, cytotoxic t-cells,
interleukin-2 production of lymphokines & cytokines.
act as chemical signals b/w wbc's (revs up immune
system)
immunomodulators that facilitate differentiation &
retinoids
suppress proliferation of cancer cells
tx: aml, aml m3 subtype, apl
all-trans retinoic acid (atra) increase maturation of promyelocytic blasts and rapid
resolution of coagulopathy r/t tx.
retinoid tx neuroblastoma.
have antitumor activity unknown moa. TERATOGENIC.
isotretinoin (accutane)
male/female pt must register iPledge (fetal exposure).
can also affect hearing & vision
proteins produced by b-lymphocytes. part of humoral
antibodies immunity of adaptive system. includes
immunoglobulins (igG, igA, igM, igE, igD)
mouse-derived MoAbs. pt develops human antimouse
murine antibodies creating high risk of hypersensitivity rx
end in -momab
very specific. directed against single antigenic
determinant on cell surface causing antibody-
dependent cellular toxicity, direct cell death,
Monoclonal antibodies
elimination of antigen/target cell that expresses the
antigen
low toxicity
-ximab moab combo of human & mouse antibodies
moab humanized, small part of mouse antibody fused
-zumab
w/ human antibody
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 2/29
, 12/17/25, 3:46 PM APHON Overview Exam || 2025 (Actual Exam) Questions with verified Answers (Latest Update 2025) UPDATE!! Flashcards | Quiz…
-umab fully humanized moabs
murine variable & human constant coupled using
chimeric moab
recombinant dna
attach low-dose radioisotopes to image residual
disease. target chemo, radiation, biotherapy to tumor
purge autologous bone marrow of cancer cells
before transplant
purpose of moabs
selectively remove t cells responsible for gvhd from
marrow prior to allogenic transplant
efficacy increased w/ chemo or radioactive
substances
tx relapsed/refractory b-cell lymphoma, cd20+, non-
rituximab hodgkins lymphoma (w/ chop), posttransplant
lymphoproliferative d/o, & chronic gvhd
act on CD20 antigen on surface of normal/malignant
rituximab moa b lymphocytes and works w/ immune system to
induce b-cell lysis
moabs that have radioactive source attached for
radiopharmaceuticals
cancer killing effect
radiopharmaceutical tx relapse/refractory low-grade
ibritumomab tiuxetan
follicular or transformed b-cell non-hodgkins
(zevalin)
lymphoma
target cd20 protein on b-cells. given prior to high
rituximab + ibritumomab
dose of radiation. causes increased toxicity and
tiuxetan
severe infusion rx
tx cd20+ follicular non-hodgkin's lymphoma. moa:
recognizes marker and signals immune response then
tositumomab + iodine 131
radioactive source locks on to moab, delivers
tositumomab (bexxar)
radiation directly to cd20 marked cells and kills
lymphoma b-cells
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 3/29
APHON Overview Exam || 2025 (Actual Exam)
Questions with verified Answers (Latest Update
2025) UPDATE!!
Save
Terms in this set (299)
modality of tx: agents that resemble body's own
defense and surveillance systems. can
biotherapy augment/modulate/restore host's immune response,
direct antitumor activity, other biological effects. side
effects typically hypersensitivity rx
tumor cells express abnormal tumor antigens on
immune surveillance surface that can be recognized/destroyed by immune
system
natural killer cells lymphocyte that recognizes/kills malignant cells
cytotoxic t cells recognize tumor-assosiated antigens and kills cells
multiple moa's & produced w/ recombinant dna.
protein capable of protecting other cells from viral
interferons infections by interfering w/ viral replication.
family of glycoproteins include: antiviral,
antiproliferative, potent immunomodulatory effects
products of immune cells to enhance cytotoxic
cytokines
activity of cells and increase immune response
leukocyte-derived. tx: hairy cell leukemia, melanoma,
alpha-interferon chronic myeloid leukemia, follicular lymphoma,
multiple myeloma, cutaneous t-cell lymphoma
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 1/29
,12/17/25, 3:46 PM APHON Overview Exam || 2025 (Actual Exam) Questions with verified Answers (Latest Update 2025) UPDATE!! Flashcards | Quiz…
beta-interferon fibroblast-derived. tx MS
t-lymphocyte derived. tx chronic granulomatus
gamma-interferon
disease
produced by t-helper cells & stimulate
growth/maturation of t-cell subsets, cytotoxic t-cells,
interleukin-2 production of lymphokines & cytokines.
act as chemical signals b/w wbc's (revs up immune
system)
immunomodulators that facilitate differentiation &
retinoids
suppress proliferation of cancer cells
tx: aml, aml m3 subtype, apl
all-trans retinoic acid (atra) increase maturation of promyelocytic blasts and rapid
resolution of coagulopathy r/t tx.
retinoid tx neuroblastoma.
have antitumor activity unknown moa. TERATOGENIC.
isotretinoin (accutane)
male/female pt must register iPledge (fetal exposure).
can also affect hearing & vision
proteins produced by b-lymphocytes. part of humoral
antibodies immunity of adaptive system. includes
immunoglobulins (igG, igA, igM, igE, igD)
mouse-derived MoAbs. pt develops human antimouse
murine antibodies creating high risk of hypersensitivity rx
end in -momab
very specific. directed against single antigenic
determinant on cell surface causing antibody-
dependent cellular toxicity, direct cell death,
Monoclonal antibodies
elimination of antigen/target cell that expresses the
antigen
low toxicity
-ximab moab combo of human & mouse antibodies
moab humanized, small part of mouse antibody fused
-zumab
w/ human antibody
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 2/29
, 12/17/25, 3:46 PM APHON Overview Exam || 2025 (Actual Exam) Questions with verified Answers (Latest Update 2025) UPDATE!! Flashcards | Quiz…
-umab fully humanized moabs
murine variable & human constant coupled using
chimeric moab
recombinant dna
attach low-dose radioisotopes to image residual
disease. target chemo, radiation, biotherapy to tumor
purge autologous bone marrow of cancer cells
before transplant
purpose of moabs
selectively remove t cells responsible for gvhd from
marrow prior to allogenic transplant
efficacy increased w/ chemo or radioactive
substances
tx relapsed/refractory b-cell lymphoma, cd20+, non-
rituximab hodgkins lymphoma (w/ chop), posttransplant
lymphoproliferative d/o, & chronic gvhd
act on CD20 antigen on surface of normal/malignant
rituximab moa b lymphocytes and works w/ immune system to
induce b-cell lysis
moabs that have radioactive source attached for
radiopharmaceuticals
cancer killing effect
radiopharmaceutical tx relapse/refractory low-grade
ibritumomab tiuxetan
follicular or transformed b-cell non-hodgkins
(zevalin)
lymphoma
target cd20 protein on b-cells. given prior to high
rituximab + ibritumomab
dose of radiation. causes increased toxicity and
tiuxetan
severe infusion rx
tx cd20+ follicular non-hodgkin's lymphoma. moa:
recognizes marker and signals immune response then
tositumomab + iodine 131
radioactive source locks on to moab, delivers
tositumomab (bexxar)
radiation directly to cd20 marked cells and kills
lymphoma b-cells
https://quizlet.com/1124083838/aphon-overview-exam-2025-actual-exam-questions-with-verified-answers-latest-update-2025-update-flash-cards/ 3/29
